Evidence map›Paper›PMID 39570560›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2024

TENT5A mediates the cancer-inhibiting effects of EGR1 by suppressing the protein stability of RPL35 in hepatocellular carcinoma.

Xuejie Min, Fen Lin, Xinge Zhao, Junming Yu, Chao Ge, Saihua Zhang, Xianxian Li, Fangyu Zhao, Taoyang Chen, Hua Tian and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xuejie MinState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai, 200032, China.
Fen LinState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai, 200032, China.
Xinge ZhaoState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai, 200032, China.
Junming YuState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai, 200032, China.
Chao GeState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai, 200032, China.
Saihua ZhangState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai, 200032, China.
Xianxian LiState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai, 200032, China.
Fangyu ZhaoState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai, 200032, China.
Taoyang ChenDepartment of Pathology, Qi Dong Liver Cancer Institute, Qidong, 226220, China.
Hua TianState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai, 200032, China.
Mingxia YanDepartment of Animal Experimental Center, Fudan University Shanghai Cancer Center, Shanghai, 201102, China.
Jinjun LiState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai, 200032, China. jjli@shsci.org.
Hong LiState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai, 200032, China. hongli@shsci.org.

Funding

National Natural Science Foundation of China 82103086National Natural Science Foundation of China 82172904National Natural Science Foundation of China 82173331Research Foundation of State Key Laboratory of Systems Medicine zz-94-23-02Research Foundation of State Key Laboratory of Systems Medicine ZZ-94-2303
6 · The paper itself

Abstract

purposeTerminal nucleotidyltransferase 5A (TENT5A), recently predicted as a non-canonical poly(A) polymerase, is critically involved in several human disorders including retinitis pigmentosa, cancer and obesity. However, the exact biological role of TENT5A in hepatocellular carcinoma (HCC) has not been elucidated.

methodsThe transcription level of TENT5A and clinical correlation were analyzed using the LIRI-JP cohort, the TCGA-LIHC cohort, and clinical tissue samples of HCC patients in our laboratory. Proliferation, migration, and invasion were detected with stably TENT5A overexpressing and knockdown HCC cells in vitro and in vivo. Chromatin immunoprecipitation and dual-luciferase reporter assay were performed to verify the binding of the target protein to DNA. Co-immunoprecipitation and GST pull-down assay combined with mass spectrometry (MS) were used to identify protein interactions.

resultsOur study presented here shows that TENT5A is downregulated in HCC tissues, suggesting a shorter overall survival for patients. Gain- and loss-of-function experiments reveal that TENT5A suppresses the proliferation and metastasis, and the residue Gly

conclusionsOur findings illustrate the role of the oncosuppressive function of TENT5A in HCC and suggest that the EGR1/TENT5A/RPL35 regulatory axis may be a promising target for therapeutic strategies in HCC.

Indexed as

Carcinoma, HepatocellularCell ProliferationEarly Growth Response Protein 1Liver NeoplasmsProtein StabilityRibosomal ProteinsAnimalsCell Line, TumorCell MovementFemaleGene Expression Regulation, NeoplasticHumansMaleMice, NudeMiddle AgedEarly Growth Response Protein 1EGR1 protein, humanRibosomal ProteinsEGR1Hepatocellular carcinomamTORTENT5ATumor suppressor

Identifiers

PMID39570560
PMCPMC12973981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.